Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1623 1673 1681 1699 1734 1759
This examiner grants 47% of resolved cases
Examiner Bahar Alawi Craigo works in Art Unit 1623 within Tech Center 1700. She has 794 resolved cases and an allowance rate of 47.1%. The median days to allowance for these cases is 1228 days. The data also shows an interview lift of 27.3%. This 27.3% lift indicates that cases involving an interview reach allowance at a higher rate than the 47.1% overall allowance rate. These figures provide a statistical overview of the prosecution environment for this examiner.
The 794 resolved cases in Tech Center 1700 establish the historical performance for Art Unit 1623. An allowance rate of 47.1% means that less than half of the applications reached a successful conclusion. The median of 1228 days to allowance represents the timeframe for the prosecution process. Because the interview lift is 27.3%, practitioners can see a benefit to conducting a formal discussion with the examiner. These data points from 794 resolved cases offer a factual summary of the outcomes for applications assigned to Bahar Alawi Craigo.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18274823 | METHODS OF TREATING CANCERS USING STING AGONISTS | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18920285 | GLYCOSYLATION INHIBITORS AS THERAPEUTICS FOR STROKE | Non-Final OA | The Regents of the University of California |
| 18323122 | NOVEL APPLICATIONS OF HYALURONIC ACID FOR TREATMENT OF PAIN AND PRURITIS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18026057 | AUTOPHAGY ACTIVATOR | Final Rejection | Resonac Corporation |
| 17996816 | COMBINATION OF FINERENONE AND A SGLT2 INHIBITOR FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR AND/OR RENAL DISEASES | Final Rejection | BAYER AKTIENGESELLSCHAFT |
| 18420277 | HIGH-EFFICIENCY GOLD RECOVERY BY ADDITIVE-INDUCED SUPRAMOLECULAR POLYMERIZATION OF CYCLODEXTRIN | Non-Final OA | Northwestern University |
| 17139665 | COMPOSITIONS AND METHODS TO ACCELERATE RESOLUTION OF ACUTE LUNG INFLAMMATION | Non-Final OA | The Johns Hopkins University |
| 17738286 | COMPOSITION FOR MAINTAINING LACTOBACILLUS DOMINANCE | Final Rejection | Kimberly-Clark Worldwide, Inc. |
| 18214162 | WATER-SOLUBLE DIETARY FIBER, USE THEREOF IN PREPARATION OF MEDICAMENT THAT PROMOTES METABOLISM OF ELLAGIC ACID INTO UROLITHIN A, AND PHARMACEUTICAL COMPOSITION | Final Rejection | ZHEJIANG UNIVERSITY |
| 18020227 | ADENOSINE-CONTAINING COMPOSITION AND METHOD FOR SUPPRESSING PRECIPITATION OF ADENOSINE | Final Rejection | Shiseido Company, Ltd. |
| 18578118 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | Non-Final OA | BOEHRINGER INGELHEIM VETMEDICA GMBH |
| 18461850 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | Final Rejection | Boehringer Ingelheim International GmbH |
| 18530865 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' BLOCKING GROUPS AND CLEAVABLE LINKERS | Non-Final OA | Illumina, Inc. |
| 18696840 | NICOTINAMIDE RIBOSIDE TRIOLEATES CHLORIDE, COMPOSITIONS CONTAINING THIS COMPOUND, AND METHODS OF MAKING AND USING THIS COMPOUND | Non-Final OA | CORNELL UNIVERSITY |
| 18483950 | METHOD FOR TREATING CANCER | Final Rejection | Colorado State University Research Foundation |
| 18566413 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | Non-Final OA | TRANSPOSON THERAPEUTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy